Correction to: Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment

Correction to: Clinical Pharmacokinetics https://doi.org/10.1007/s40262-023-01215-9

In this article Figs. 1 and 2 were wrongly numbered; Fig. 1 should have been Fig. 2 and vice versa as shown below.

Fig. 1

Geometric mean concentration time-profiles for glepaglutide. Vertical bars indicate 95% CIs; glepaglutide = parent + M1 + M2; normal renal function (eGFR ≥ 90 mL/min/1.73 m²); severe/ESRD: severe renal impairment (eGFR 15 to < 30 mL/min/1.73 m²) or end stage renal disease (eGFR < 15 mL/min/1.73 m²); parent: unmetabolized glepaglutide; M1: glepaglutide_1–35; M2: glepaglutide_1–34. CI confidence interval, eGFR estimated glomerular filtration rate, ESRD end-stage renal disease

Fig. 2

Forest plots of C_max and AUC_0–168 h for glepaglutide. The primary pharmacokinetic endpoints (C_max and AUC_0–168 h) were log transformed and evaluated using an analysis of variance (ANOVA), with renal function as fixed effect. Ratios of geometric least-squares means (impaired renal function/normal renal function) and corresponding 90% confidence intervals (CIs) were estimated from the model. Glepaglutide = parent + M1 + M2; normal: normal renal function; severe/ESRD: severe renal impairment (eGFR 15 to < 30 mL/min/1.73 m²) or end stage renal disease (eGFR < 15 mL/min/1.73 m²); parent: unmetabolized glepaglutide; M1: glepaglutide_1–35; M2: glepaglutide_1–34. CI confidence interval, eGFR estimated glomerular filtration rate, ESRD end-stage renal disease

The original article has been corrected.